Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

Maternal Vitamin D Prevents Abnormal Dopaminergic Development and Function in a Mouse Model of Prenatal Immune Activation.

Luan W, Hammond LA, Vuillermot S, Meyer U, Eyles DW.

Sci Rep. 2018 Jun 27;8(1):9741. doi: 10.1038/s41598-018-28090-w.

2.

Developmental Vitamin D (DVD) Deficiency Reduces Nurr1 and TH Expression in Post-mitotic Dopamine Neurons in Rat Mesencephalon.

Luan W, Hammond LA, Cotter E, Osborne GW, Alexander SA, Nink V, Cui X, Eyles DW.

Mol Neurobiol. 2018 Mar;55(3):2443-2453. doi: 10.1007/s12035-017-0497-3. Epub 2017 Apr 1.

PMID:
28365874
3.

Functional decline at the aging neuromuscular junction is associated with altered laminin-α4 expression.

Lee KM, Chand KK, Hammond LA, Lavidis NA, Noakes PG.

Aging (Albany NY). 2017 Mar 14;9(3):880-899. doi: 10.18632/aging.101198.

4.

A method for the three-dimensional reconstruction of Neurobiotin™-filled neurons and the location of their synaptic inputs.

Fogarty MJ, Hammond LA, Kanjhan R, Bellingham MC, Noakes PG.

Front Neural Circuits. 2013 Oct 1;7:153. doi: 10.3389/fncir.2013.00153. eCollection 2013.

5.

A trans-Golgi network golgin is required for the regulated secretion of TNF in activated macrophages in vivo.

Lieu ZZ, Lock JG, Hammond LA, La Gruta NL, Stow JL, Gleeson PA.

Proc Natl Acad Sci U S A. 2008 Mar 4;105(9):3351-6. doi: 10.1073/pnas.0800137105. Epub 2008 Feb 28.

6.

Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study.

Rodon J, Garrison M, Hammond LA, de Bono J, Smith L, Forero L, Hao D, Takimoto C, Lambert JM, Pandite L, Howard M, Xie H, Tolcher AW.

Cancer Chemother Pharmacol. 2008 Oct;62(5):911-9. doi: 10.1007/s00280-007-0672-8. Epub 2008 Feb 27.

PMID:
18301896
7.

Subcompartments of the macrophage recycling endosome direct the differential secretion of IL-6 and TNFalpha.

Manderson AP, Kay JG, Hammond LA, Brown DL, Stow JL.

J Cell Biol. 2007 Jul 2;178(1):57-69.

8.

EGF induces macropinocytosis and SNX1-modulated recycling of E-cadherin.

Bryant DM, Kerr MC, Hammond LA, Joseph SR, Mostov KE, Teasdale RD, Stow JL.

J Cell Sci. 2007 May 15;120(Pt 10):1818-28.

9.

A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignancies.

Rowinsky EK, Beeram M, Hammond LA, Schwartz G, De Bono J, Forouzesh B, Chu Q, Latz JE, Hong S, John W, Nguyen B.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):532-9.

10.

Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors.

Patnaik A, Wood D, Tolcher AW, Hamilton M, Kreisberg JI, Hammond LA, Schwartz G, Beeram M, Hidalgo M, Mita MM, Wolf J, Nadler P, Rowinsky EK.

Clin Cancer Res. 2006 Dec 15;12(24):7406-13.

11.

Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors.

Mita AC, Hammond LA, Bonate PL, Weiss G, McCreery H, Syed S, Garrison M, Chu QS, DeBono JS, Jones CB, Weitman S, Rowinsky EK.

Clin Cancer Res. 2006 Sep 1;12(17):5207-15.

12.

Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction.

Schaaf LJ, Hammond LA, Tipping SJ, Goldberg RM, Goel R, Kuhn JG, Miller LL, Compton LD, Cisar LA, Elfring GL, Gruia G, McGovren JP, Pirotta N, Yin D, Sharma A, Duncan BA, Rothenberg ML.

Clin Cancer Res. 2006 Jun 15;12(12):3782-91.

13.

A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.

Mita MM, Rowinsky EK, Forero L, Eckhart SG, Izbicka E, Weiss GR, Beeram M, Mita AC, de Bono JS, Tolcher AW, Hammond LA, Simmons P, Berg K, Takimoto C, Patnaik A.

Cancer Chemother Pharmacol. 2007 Feb;59(2):165-74. Epub 2006 May 31.

PMID:
16736151
14.

Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer.

Tolcher AW, Hao D, de Bono J, Miller A, Patnaik A, Hammond LA, Smetzer L, Van Wart Hood J, Merritt J, Rowinsky EK, Takimoto C, Von Hoff D, Eckhardt SG.

J Clin Oncol. 2006 May 1;24(13):2052-8.

PMID:
16648505
15.

Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function.

Mita AC, Sweeney CJ, Baker SD, Goetz A, Hammond LA, Patnaik A, Tolcher AW, Villalona-Calero M, Sandler A, Chaudhuri T, Molpus K, Latz JE, Simms L, Chaudhary AK, Johnson RD, Rowinsky EK, Takimoto CH.

J Clin Oncol. 2006 Feb 1;24(4):552-62. Epub 2006 Jan 3.

PMID:
16391300
16.

Phase I and pharmacokinetic study of sequences of the rebeccamycin analogue NSC 655649 and cisplatin in patients with advanced solid tumors.

Ricart AD, Hammond LA, Kuhn JG, Takimoto CH, Goetz A, Forouzesh B, Forero L, Ochoa-Bayona JL, Berg K, Tolcher AW, Rowinsky EK.

Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8728-36.

17.

A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer.

Mita MM, Ochoa L, Rowinsky EK, Kuhn J, Schwartz G, Hammond LA, Patnaik A, Yeh IT, Izbicka E, Berg K, Tolcher AW.

Ann Oncol. 2006 Feb;17(2):313-21. Epub 2005 Dec 1.

PMID:
16322117
18.

Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors.

Cunningham C, Appleman LJ, Kirvan-Visovatti M, Ryan DP, Regan E, Vukelja S, Bonate PL, Ruvuna F, Fram RJ, Jekunen A, Weitman S, Hammond LA, Eder JP Jr.

Clin Cancer Res. 2005 Nov 1;11(21):7825-33.

19.

A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors.

Ebbinghaus S, Rubin E, Hersh E, Cranmer LD, Bonate PL, Fram RJ, Jekunen A, Weitman S, Hammond LA.

Clin Cancer Res. 2005 Nov 1;11(21):7807-16.

20.

E-cadherin transport from the trans-Golgi network in tubulovesicular carriers is selectively regulated by golgin-97.

Lock JG, Hammond LA, Houghton F, Gleeson PA, Stow JL.

Traffic. 2005 Dec;6(12):1142-56.

21.

Acute retinal toxicity from the novel anti-tumor agent, Irofulven.

Melendez RF, Harrison JM, Rowinsky EK, Hammond LA, Fitzsimmons TD.

Doc Ophthalmol. 2004 May;108(3):249-51. No abstract available.

PMID:
15573949
22.

ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas.

de Bono JS, Tolcher AW, Forero A, Vanhove GF, Takimoto C, Bauer RJ, Hammond LA, Patnaik A, White ML, Shen S, Khazaeli MB, Rowinsky EK, LoBuglio AF.

Clin Cancer Res. 2004 Nov 15;10(22):7555-65.

23.

Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity.

de Bono JS, Rha SY, Stephenson J, Schultes BC, Monroe P, Eckhardt GS, Hammond LA, Whiteside TL, Nicodemus CF, Cermak JM, Rowinsky EK, Tolcher AW.

Ann Oncol. 2004 Dec;15(12):1825-33.

PMID:
15550589
24.

Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study.

Calvo E, Tolcher AW, Hammond LA, Patnaik A, de Bono JS, Eiseman IA, Olson SC, Lenehan PF, McCreery H, Lorusso P, Rowinsky EK.

Clin Cancer Res. 2004 Nov 1;10(21):7112-20.

25.

A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties.

Syed S, Takimoto C, Hidalgo M, Rizzo J, Kuhn JG, Hammond LA, Schwartz G, Tolcher A, Patnaik A, Eckhardt SG, Rowinsky EK.

Clin Cancer Res. 2004 Oct 1;10(19):6512-21.

26.

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.

Pérez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabárbara P, Bonomi P.

J Clin Oncol. 2004 Aug 15;22(16):3238-47.

PMID:
15310767
27.

A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer.

Tolcher AW, Kuhn J, Schwartz G, Patnaik A, Hammond LA, Thompson I, Fingert H, Bushnell D, Malik S, Kreisberg J, Izbicka E, Smetzer L, Rowinsky EK.

Clin Cancer Res. 2004 Aug 1;10(15):5048-57.

28.

Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.

Chu QS, Hammond LA, Schwartz G, Ochoa L, Rha SY, Denis L, Molpus K, Roedig B, Letrent SP, Damle B, DeCillis AP, Rowinsky EK.

Clin Cancer Res. 2004 Aug 1;10(15):4913-21.

29.

An antagonist of retinoic acid receptors more effectively inhibits growth of human prostate cancer cells than normal prostate epithelium.

Keedwell RG, Zhao Y, Hammond LA, Wen K, Qin S, Atangan LI, Shurland DL, Wallace DM, Bird R, Reitmair A, Chandraratna RA, Brown G.

Br J Cancer. 2004 Aug 2;91(3):580-8.

30.

An image worth a thousand lives?

Hammond LA, Cavanaugh SX, Thomas CR.

Nat Biotechnol. 2004 Jun;22(6):677-8. No abstract available.

PMID:
15175685
31.

A retinoid-related molecule that does not bind to classical retinoid receptors potently induces apoptosis in human prostate cancer cells through rapid caspase activation.

Keedwell RG, Zhao Y, Hammond LA, Qin S, Tsang KY, Reitmair A, Molina Y, Okawa Y, Atangan LI, Shurland DL, Wen K, Wallace DM, Bird R, Chandraratna RA, Brown G.

Cancer Res. 2004 May 1;64(9):3302-12.

32.

A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms.

Hammond LA, Eckardt JR, Kuhn JG, Gerson SL, Johnson T, Smith L, Drengler RL, Campbell E, Weiss GR, Von Hoff DD, Rowinsky EK.

Clin Cancer Res. 2004 Mar 1;10(5):1645-56.

33.

A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.

Forouzesh B, Takimoto CH, Goetz A, Diab S, Hammond LA, Smetzer L, Schwartz G, Gazak R, Callaghan JT, Von Hoff DD, Rowinsky EK.

Clin Cancer Res. 2003 Nov 15;9(15):5540-9.

34.

Pharmacokinetic evaluation of gefitinib when administered with chemotherapy.

Hammond LA.

Clin Lung Cancer. 2003 Sep;5 Suppl 1:S18-21. Review.

PMID:
14641990
35.

A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies.

Patnaik A, Eckhardt SG, Izbicka E, Tolcher AA, Hammond LA, Takimoto CH, Schwartz G, McCreery H, Goetz A, Mori M, Terada K, Gentner L, Rybak ME, Richards H, Zhang S, Rowinsky EK.

Clin Cancer Res. 2003 Oct 15;9(13):4761-71.

36.

Positron emission tomography (PET): expanding the horizons of oncology drug development.

Hammond LA, Denis L, Salman U, Jerabek P, Thomas CR Jr, Kuhn JG.

Invest New Drugs. 2003 Aug;21(3):309-40. Review.

PMID:
14578681
37.

A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.

Herbst RS, Hammond LA, Carbone DP, Tran HT, Holroyd KJ, Desai A, Williams JI, Bekele BN, Hait H, Allgood V, Solomon S, Schiller JH.

Clin Cancer Res. 2003 Sep 15;9(11):4108-15.

38.

A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies.

Garrison MA, Hammond LA, Geyer CE Jr, Schwartz G, Tolcher AW, Smetzer L, Figueroa JA, Ducharme M, Coyle J, Takimoto CH, De Jager RL, Rowinsky EK.

Clin Cancer Res. 2003 Jul;9(7):2527-37.

39.

Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients.

Malik SN, Siu LL, Rowinsky EK, deGraffenried L, Hammond LA, Rizzo J, Bacus S, Brattain MG, Kreisberg JI, Hidalgo M.

Clin Cancer Res. 2003 Jul;9(7):2478-86.

40.

A Phase I and pharmacokinetic study of squalamine, an aminosterol angiogenesis inhibitor.

Hao D, Hammond LA, Eckhardt SG, Patnaik A, Takimoto CH, Schwartz GH, Goetz AD, Tolcher AW, McCreery HA, Mamun K, Williams JI, Holroyd KJ, Rowinsky EK.

Clin Cancer Res. 2003 Jul;9(7):2465-71.

41.

A phase I study of bizelesin, a highly potent and selective DNA-interactive agent, in patients with advanced solid malignancies.

Schwartz GH, Patnaik A, Hammond LA, Rizzo J, Berg K, Von Hoff DD, Rowinsky EK.

Ann Oncol. 2003 May;14(5):775-82.

PMID:
12702533
42.

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules.

Tolcher AW, Gerson SL, Denis L, Geyer C, Hammond LA, Patnaik A, Goetz AD, Schwartz G, Edwards T, Reyderman L, Statkevich P, Cutler DL, Rowinsky EK.

Br J Cancer. 2003 Apr 7;88(7):1004-11.

43.

Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study.

Tolcher AW, Ochoa L, Hammond LA, Patnaik A, Edwards T, Takimoto C, Smith L, de Bono J, Schwartz G, Mays T, Jonak ZL, Johnson R, DeWitte M, Martino H, Audette C, Maes K, Chari RV, Lambert JM, Rowinsky EK.

J Clin Oncol. 2003 Jan 15;21(2):211-22.

PMID:
12525512
44.

A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies.

Rowinsky EK, Rizzo J, Ochoa L, Takimoto CH, Forouzesh B, Schwartz G, Hammond LA, Patnaik A, Kwiatek J, Goetz A, Denis L, McGuire J, Tolcher AW.

J Clin Oncol. 2003 Jan 1;21(1):148-57.

PMID:
12506184
45.

HER-targeted tyrosine-kinase inhibitors.

Baselga J, Hammond LA.

Oncology. 2002;63 Suppl 1:6-16. Review.

PMID:
12422050
46.

The prospects of retinoids in the treatment of prostate cancer.

Hammond LA, Brown G, Keedwell RG, Durham J, Chandraratna RA.

Anticancer Drugs. 2002 Sep;13(8):781-90. Review. Erratum in: Anticancer Drugs. 2002 Nov;13(10):1077-8.

PMID:
12394261
47.

A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.

Siu LL, Rowinsky EK, Hammond LA, Weiss GR, Hidalgo M, Clark GM, Moczygemba J, Choi L, Linnartz R, Barbet NC, Sklenar IT, Capdeville R, Gan G, Porter CW, Von Hoff DD, Eckhardt SG.

Clin Cancer Res. 2002 Jul;8(7):2157-66.

48.

A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies.

Patnaik A, Rowinsky EK, Villalona MA, Hammond LA, Britten CD, Siu LL, Goetz A, Felton SA, Burton S, Valone FH, Eckhardt SG.

Clin Cancer Res. 2002 Jul;8(7):2142-8. Review.

49.

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial.

Ranson M, Hammond LA, Ferry D, Kris M, Tullo A, Murray PI, Miller V, Averbuch S, Ochs J, Morris C, Feyereislova A, Swaisland H, Rowinsky EK.

J Clin Oncol. 2002 May 1;20(9):2240-50.

PMID:
11980995
50.

Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks.

Rothenberg ML, Kuhn JG, Schaaf LJ, Rodriguez GI, Eckhardt SG, Villalona-Calero MA, Rinaldi DA, Hammond LA, Hodges S, Sharma A, Elfring GL, Petit RG, Locker PK, Miller LL, von Hoff DD.

Ann Oncol. 2001 Nov;12(11):1631-41.

PMID:
11822765

Supplemental Content

Loading ...
Support Center